So we have 668m shares on issue.
Cash is approximately A$18m.
At 9c we have a market cap of A$60mAt AUD/USD at 62c, this equates to an enterprise value of US$26m
After the results across DMD, Limb Girdle, Long Covid, the potential of the combination studies, the high likelihood of our P2b being an approve able trial, witnessing Sarepta sales of >US$200m for the QUARTER for drugs that show no clinical efficacy..
The low valuation of this company is a disgrace.
I would love to know lots of different peoples opinions on what key catalysts will improve the outlook for the share price?
Thanks in Advance.
ANP Value
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.5¢ | $38.88K | 514.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 39300 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 26315 | 1 |
View Market Depth
| Last trade - 15.19pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.8¢ | 7.5¢ | 112689 | ||
| Last updated 15.50pm 21/05/2024 ? | |||||
| PER (ASX) Chart |